{"prompt": "['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'The exploratory objectives are to characterize the pharmacokinetics and incidence of', 'anti-therapeutic antibodies (ATAs) against rovalpituzumab tesirine, to evaluate', 'pharmacodynamic and predictive biomarkers in blood and tumor for association with', 'sensitivity, efficacy and safety, to explore the DLL3 expression in circulating tumor cells', '(CTCs) for association with efficacy, and to assess EQ-5D-5L during treatment with', 'rovalpituzumab tesirine.', 'Has been changed to read:', 'The primary objective of this study is to evaluate if rovalpituzumab tesirine improves', 'progression-free survival, assessed by CRAC, and overall survival in subjects with', 'extensive-stage SCLC tumors with a high level of DLL3 expression (DLL3high who have', 'ongoing clinical benefit (SD, PR, or CR) following the completion of 4 cycles of', 'first-line, platinum-based chemotherapy (cisplatin or carboplatin plus irinotecan or', 'etoposide) compared to placebo.', 'The secondary objectives are:', 'To evaluate if rovalpituzumab tesirine improves progression-free survival by', 'CRAC and overall survival in all randomized subjects compared to placebo.', 'To assess change in patient reported outcomes (PRO) with physical', 'functioning as measured by the EORTC QLQ-C30questionnaire in all', 'randomized subjects compared to placebo.', 'The exploratory objectives are:', 'To evaluate rovalpituzumab tesirine anti-tumor activity by determining', 'objective response rate (ORR), clinical benefit rate (CBR), and duration of', 'responses (DOR) by CRAC and investigator assessment in DLL3high and in', 'all', 'randomized subjects.', 'To evaluate if rovalpituzumab tesirine improves progression-free survival by', 'investigator assessment compared to placebo in DLL3high and in all', 'randomized subjects.', '163']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'To assess change from baseline in all patient reported outcomes (PRO)', 'domains (except physical functioning) measured by EORTC QLQ-C30/LC13', 'and EQ-5D-5L.', 'To characterize the pharmacokinetics and incidence of anti-therapeutic', 'antibodies (ATAs) against rovalpituzumab tesirine.', 'To evaluate pharmacodynamic and predictive biomarkers in blood and tumor', 'for association with sensitivity, efficacy and safety.', 'To explore the DLL3 expression in circulating tumor cells (CTCs) for', 'association with efficacy.', 'Section 5.1 Overall Study Design and Plan: Description', 'Second paragraph, last sentence previously read:', 'Approximately 275 clinical sites will participate.', 'Has been changed to read:', 'Approximately 300 clinical sites will participate.', 'Figure 1. Study Schema', 'Footnote \"3.\" previously read:', 'At least 3 but no more than 9 weeks between the administration of the last cycle of', 'platinum-based chemotherapy and randomization.', 'Has been changed to read:', 'Subject is eligible to be randomized at least 3 but no more than 9 weeks from Day 1 of the', 'fourth cycle of first-line platinum-based chemotherapy.', '164']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Section 5.2 Selection of Study Population', 'Add: new second paragraph', 'For the purposes of study eligibility, limited stage disease SCLC (LD-SCLC) is defined as', 'a disease confined to the hemithorax of origin, with or without the involvement of', 'regional lymph nodes, including ipsilateral and contralateral hilar, ipsilateral and', 'contralateral mediastinal, and ipsilateral supraclavicular nodes. Extensive stage disease', 'SCLC (ED-SCLC) is defined as all other SCLC.', 'Section 5.2.1 Inclusion Criteria', 'Criterion 1, 3, and 5 previously read:', '1.', 'Subject must voluntarily sign and date an informed consent, approved by an', 'Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the', 'initiation of any screening or study-specific procedures and should be willing and', 'able to comply with parameters as outlined in the protocol.', '3.', 'Histologically or cytologically confirmed extensive-stage SCLC with ongoing', 'clinical benefit (SD, PR, or CR per RECIST v.1.1) following completion of 4 cycles', 'of first-line platinum-based therapy (cisplatin or carboplatin in combination with', 'etoposide or irinotecan).', '5.', 'At least 3 but no more than 9 weeks between the administration of the last cycle of', 'platinum-based chemotherapy and randomization.', 'Has been changed to read:', '1.', \"Subject or the subject's legally acceptable representative must voluntarily sign and\", 'date an informed consent, approved by an Independent Ethics Committee', '(IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or', 'study-specific procedures and should be willing and able to comply with parameters', 'as outlined in the protocol.', '165']\n\n###\n\n", "completion": "END"}